What are the appropriate indications, loading and maintenance dosing, monitoring recommendations, contraindications, and alternative anticonvulsants for phenytoin therapy?

Phenytoin Therapy: Clinical Guide

Primary Indications

Phenytoin is indicated for generalized tonic-clonic status epilepticus, prevention and treatment of neurosurgical seizures, and short-term substitution when oral administration is not possible 1. The drug should not be used empirically in coma of unknown etiology 2.

Status Epilepticus Dosing

For status epilepticus, administer a loading dose of 15-20 mg/kg IV in adults (maximum 1000 mg initially, up to 40 mg/kg total if needed) at a rate not exceeding 50 mg/minute 2, 1. In pediatric patients, use 15-20 mg/kg at 1-3 mg/kg/min or 50 mg/min, whichever is slower 2, 1.

• The loading dose should be followed by maintenance doses of 100 mg every 6-8 hours 1
• Continuous ECG, blood pressure, and respiratory monitoring is essential during administration 2, 1
• Therapeutic serum levels (10-20 mcg/mL total, 1-2 mcg/mL unbound) are typically achieved within minutes of IV infusion completion 3
• If seizures persist after phenytoin loading, consider alternative agents or general anesthesia 1

Critical pitfall: Neonates have increased toxicity risk due to decreased protein binding; phenobarbital is preferred in this population 2.

Non-Emergent Loading and Maintenance

For non-emergent situations, administer 10-15 mg/kg IV at ≤50 mg/min in adults, followed by maintenance dosing every 6-8 hours 1. Oral phenytoin should be used whenever possible due to risks of cardiac and local toxicity with IV administration 3.

Weight-based dosing is critical: Studies demonstrate that higher weight-based loading doses (median 19.1 mg/kg vs 12.6 mg/kg) significantly predict achievement of therapeutic levels 4. In overweight patients (>120% ideal body weight), use adjusted body weight rather than actual body weight for dose calculation to avoid supratherapeutic levels 5.

Route of Administration Considerations

Intramuscular administration should be avoided due to erratic absorption, risk of necrosis, abscess formation, and delayed peak levels (up to 24 hours) 2, 1. If IM administration is unavoidable, a dose 50% greater than oral is required, with subsequent dose reduction by 50% when returning to oral therapy 1.

When substituting IV for oral phenytoin, recognize that IV phenytoin is 100% bioavailable versus approximately 90% for oral formulations, potentially causing modest serum concentration increases 1.

Monitoring Requirements

Measure trough phenytoin levels just prior to the next scheduled dose; peak levels should be obtained at expected peak concentration to assess for dose-related toxicity 1.

• Serum levels do not need rechecking before ED discharge, but outpatient monitoring is essential 3
• In renal/hepatic disease or hypoalbuminemia, monitor unbound phenytoin concentrations as these are more clinically relevant 1
• For patients on phenytoin with cycloserine, monitor phenytoin levels as interactions occur 6
• Oral maintenance dosing without loading achieves therapeutic levels in 3-7 days 3

Optimal timing for pediatric monitoring: Measure levels at 2 hours and 12 hours after loading dose to safely adjust dosing 7.

Adverse Effects and Contraindications

Absolute Contraindications

• Hypersensitivity to phenytoin or hydantoins 1
• Sinus bradycardia, sino-atrial block, second/third-degree AV block, Adams-Stokes syndrome 1
• Prior acute hepatotoxicity from phenytoin 1
• Coadministration with delavirdine 1

Major Adverse Effects

IV phenytoin carries significant risks: hypotension, cardiac arrhythmias (including ventricular fibrillation and death), purple glove syndrome, tissue necrosis, and phlebitis 3, 8. These effects relate to propylene glycol (40%) and ethanol (10%) content with pH 12 3.

• Dose-related CNS effects: ataxia, nystagmus, tremor, somnolence, mental confusion 3
• Reduce infusion rate if heart rate decreases by 10 beats/min 2
• Monitor for respiratory depression, especially when combined with benzodiazepines 2

Serious dermatologic reactions: Discontinue immediately at first sign of rash unless clearly unrelated. If Stevens-Johnson syndrome/toxic epidermal necrolysis suspected, do not resume 1.

DRESS syndrome: If hypersensitivity signs present, evaluate immediately and discontinue if alternative etiology cannot be established 1.

Alternative Anticonvulsants

For Benzodiazepine-Refractory Status Epilepticus

The 2024 ACEP guidelines and recent evidence support multiple second-line options beyond phenytoin 9. Valproate demonstrates equal or superior efficacy with potentially fewer adverse effects 10, 3:

• Valproate: 20-40 mg/kg IV (typically 30 mg/kg) at 6 mg/kg/hour achieved seizure control in 79% as second-line therapy versus 25% with phenytoin 10
• Both valproate and phenytoin showed 88% success rates within 20 minutes, but valproate caused no hypotension versus 12% with phenytoin 10

Levetiracetam is increasingly preferred over phenytoin due to lack of cardiac toxicity, no enzymatic induction, and simpler administration 8. If levetiracetam fails, add valproate, lacosamide, or phenytoin before third-line treatment 8.

Phenobarbital showed equal efficacy to lorazepam, phenytoin, and diazepam/phenytoin combinations in the VA Cooperative Study, though respiratory depression and hypotension risks exist 3.

Fosphenytoin Advantages

Fosphenytoin, the water-soluble prodrug of phenytoin, has a superior safety profile with significantly lower rates of phlebitis, purple glove syndrome, tissue necrosis, cardiac toxicity, and hypotension 3. However, acquisition costs are considerably higher than IV or oral phenytoin 3.

• IM fosphenytoin produces therapeutic levels within 1 hour 3
• Dosing adjustments needed when switching between sodium salt and free acid formulations (approximately 8% difference in drug content) 1

Special Populations

Pregnancy: Prenatal phenytoin exposure increases risks for congenital malformations and adverse developmental outcomes 3, 1.

Renal/hepatic impairment: Base monitoring on unbound phenytoin fractions 1. Dose adjustments required based on creatinine clearance and hepatic function.

Enteral nutrition: Holding EN for phenytoin administration does not impact daily nutrition goal attainment and maintains therapeutic phenytoin levels 11. Implement EN holding protocols without concern for nutritional compromise.